title: Comparison of 2-year clinical outcomes with sirolimus and paclitaxel-eluting stents for patients with diabetes: results of the Registro Regionale AngiopLastiche Emilia-Romagna Registry.
abstract: BACKGROUND
  Long-term outcomes of percutaneous coronary interventions (PCI) with sirolimus-eluting stents (SES) compared to paclitaxel-eluting-stents (PES) in unselected diabetics in routine practice is still debated.
  
  
  OBJECTIVE
  This study compared the 2-year incidence of MACE (all-cause mortality, nonfatal myocardial infarction and target vessel revascularization) of SES and PES in a real-world setting of patients with diabetes.
  
  
  METHODS
  Observational, multicenter, nonrandomized study.
  
  
  METHODS
  Prospective web-based registry (REAL Registry; study period, 2002-2005) comprising all 13 hospitals performing PCI.
  
  
  METHODS
  Among the 945 eligible patients treated with either SES alone (n = 606) or PES alone (n = 339), 29% were insulin-requiring, 72% had multivessel coronary disease, 26% had prior myocardial infarction and 10% had poor left ventricular function.
  
  
  METHODS
  Unadjusted and propensity score-adjusted 2-year clinical outcome.
  
  
  RESULTS
  After propensity score adjustment, 2-year MACE incidence in the SES and PES groups was equivalent (23.3% vs. 23.7%, HR 1.01, 95%CI 0.72-1.42, P = 0.96). Adjusted 2-year angiographic stent thrombosis occurred in 1.1% of the SES patients versus 2.6% of the PES patients (P = 0.15). In this large, real-world, diabetic population treated with DES, there was no difference in outcome between SES and PES. Further studies are needed to demonstrate the long-term safety of different types of DES in patients with diabetes.
authors: Department of Cardiology, S. Maria delle Croci Hospital, Azienda Unitá Sanitaria Locale Ravenna, Viale Randi 5, Ravenna 48100, Italy. balducelli@libero.it
authors: Marco
authors: M
authors: Balducelli
authors: Paolo
authors: P
authors: Ortolani
authors: Paolo
authors: P
authors: Marzaroli
authors: Giancarlo
authors: G
authors: Piovaccari
authors: Alberto
authors: A
authors: Menozzi
authors: Antonio
authors: A
authors: Manari
authors: Pietro
authors: P
authors: Sangiorgio
authors: Fabio
authors: F
authors: Tarantino
authors: Rosario
authors: R
authors: Rossi
authors: Aleardo
authors: A
authors: Maresta
authors: Stefano
authors: S
authors: Tondi
authors: Francesco
authors: F
authors: Passerini
authors: Paolo
authors: P
authors: Guastaroba
authors: Roberto
authors: R
authors: Grilli
authors: Antonio
authors: A
authors: Marzocchi
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000628:therapy*; D003920:Diabetes Mellitus; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D020407:Internet; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D057216:Propensity Score; D012042:Registries; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage*
chemical_list: D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus